Header Logo

Connection

JIUN-KAE JACK LEE to Survival Analysis

Back to Details
This is a "connection" page, showing publications JIUN-KAE JACK LEE has written about Survival Analysis.
JIUN-KAE JACK LEE
Connection Strength
0.416
Survival Analysis
  1. Demystify statistical significance--time to move on from the p value to bayesian analysis. J Natl Cancer Inst. 2011 Jan 05; 103(1):2-3.
    View in: PubMed
    Score: 0.165
  2. A systems biology-based gene expression classifier of glioblastoma predicts survival with solid tumors. PLoS One. 2009 Jul 17; 4(7):e6274.
    View in: PubMed
    Score: 0.037
  3. Decision analysis for prophylactic cranial irradiation for patients with small-cell lung cancer. J Clin Oncol. 2006 Aug 01; 24(22):3597-603.
    View in: PubMed
    Score: 0.030
  4. Estimation of k for the poly-k test with application to animal carcinogenicity studies. Stat Med. 2003 Aug 30; 22(16):2619-36.
    View in: PubMed
    Score: 0.025
  5. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.
    View in: PubMed
    Score: 0.013
  6. Surgical treatment of multiple brain metastases. J Neurosurg. 1993 Aug; 79(2):210-6.
    View in: PubMed
    Score: 0.012
  7. Tissue platinum concentration and tumor response in non-small-cell lung cancer. J Clin Oncol. 2012 Sep 20; 30(27):3345-52.
    View in: PubMed
    Score: 0.012
  8. A note on confidence limits for quartiles with right censored data. Stat Med. 1989 Oct; 8(10):1269-76.
    View in: PubMed
    Score: 0.009
  9. Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila). 2009 Aug; 2(8):702-11.
    View in: PubMed
    Score: 0.009
  10. Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.
    View in: PubMed
    Score: 0.008
  11. Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst. 2006 Apr 05; 98(7):441-50.
    View in: PubMed
    Score: 0.007
  12. Akt activation correlates with adverse outcome in tongue cancer. Cancer. 2005 Dec 01; 104(11):2430-6.
    View in: PubMed
    Score: 0.007
  13. Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol. 2005 Mar 20; 23(9):1911-20.
    View in: PubMed
    Score: 0.007
  14. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.
    View in: PubMed
    Score: 0.007
  15. Loss of Fhit expression in head and neck squamous cell carcinoma and its potential clinical implication. Clin Cancer Res. 2004 Aug 15; 10(16):5554-7.
    View in: PubMed
    Score: 0.007
  16. The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med. 2004 Apr 01; 350(14):1405-13.
    View in: PubMed
    Score: 0.006
  17. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer. Clin Lung Cancer. 2003 Jul; 5(1):40-5.
    View in: PubMed
    Score: 0.006
  18. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol. 2002 Apr 15; 20(8):2045-52.
    View in: PubMed
    Score: 0.006
  19. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002 Jan 15; 20(2):364-70.
    View in: PubMed
    Score: 0.006
  20. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res. 2001 Apr; 7(4):861-7.
    View in: PubMed
    Score: 0.005
  21. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol. 2000 Dec 01; 18(23):3904-11.
    View in: PubMed
    Score: 0.005
  22. Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma. Clin Cancer Res. 2000 Mar; 6(3):790-7.
    View in: PubMed
    Score: 0.005
  23. Prognostic implication of microsatellite alteration profiles in early-stage non-small cell lung cancer. Clin Cancer Res. 2000 Feb; 6(2):559-65.
    View in: PubMed
    Score: 0.005
  24. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst. 1999 May 05; 91(9):763-71.
    View in: PubMed
    Score: 0.005
  25. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol. 1999 Mar; 17(3):976-83.
    View in: PubMed
    Score: 0.005
  26. bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res. 1996 Dec; 2(12):2015-22.
    View in: PubMed
    Score: 0.004
  27. The incidence of second primary tumors in long-term survivors of small-cell lung cancer. J Clin Oncol. 1992 Oct; 10(10):1519-24.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.